-
Mashup Score: 16Isatuximab, Carfilzomib, Lenalidomide, and Dexamethasone Induction in Newly Diagnosed Myeloma: Analysis of the MIDAS Trial - 2 month(s) ago
Key Points. Induction therapy with IsaKRD in the MIDAS study yielded the highest pre-transplant MRD-negativity rates ever reported in TE NDMM patientsThe f
Source: ashpublications.orgCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 2Samer Al Hadidi: The longest follow up of any myeloma phase III clinical trial - OncoDaily - 2 month(s) ago
Samer Al Hadidi: The longest follow up of any myeloma phase III clinical trial / Anup Trikannad, Asis Shrestha, cancer, Meera Mohan, multiple myeloma,
Source: oncodaily.comCategories: General Medicine News, Hem/OncsTweet-
RT @oncodaily: The longest follow up of any myeloma phase III clinical trial - @HadidiSamer @UAMSMyeloma https://t.co/SAMEvVCA1L #Cancer…
-
-
Mashup Score: 4Adverse Metaphase Cytogenetics Can Be Overcome by Adding Bortezomib and Thalidomide to Fractionated Melphalan Transplants - 2 month(s) ago
Abstract. Purpose: To determine whether a reduction in the intensity of Total Therapy (TT) reduces toxicity and maintains efficacy.Experimental Design: A total of 289 patients with gene expression profiling (GEP70)-defined low-risk multiple myeloma were randomized between a standard arm (TT4-S) and a light arm (TT4-L). TT4-L employed one instead of two inductions and consolidations. To compensate for potential loss of efficacy of TT4-L, bortezomib and thalidomide were added to fractionated melphalan 50 mg/m2/d for 4 days.Results: Grade ≥3 toxicities and treatment-related mortalities were not reduced in TT4-L. Complete response (CR) rates were virtually identical (P = 0.2; TT4-S, 59%; TT4-L, 61% at 2 years), although CR duration was superior with TT4-S (P = 0.05; TT4-S, 87%; TT4-L, 81% at 2 years). With a median follow-up of 4.5 years, there was no difference in overall survival (OS) and progression-free survival (PFS). Whereas metaphase cytogenetic abnormalities (CAs) tended to be an a
Source: aacrjournals.orgCategories: General Medicine News, Hem/OncsTweet-
We will be publishing soon data on TT IV focusing only on patients with standard risk myeloma All those approaches didn’t use upfront Dara (anti-CD38) therapy and intended to do tandem auto transplant Earlier results published a while ago: https://t.co/c7AN0kns5l
-
-
Mashup Score: 82Long Term Follow up of Total Therapy IV: A Phase III Clinical Trial for Standard Risk Multiple Myeloma - 2 month(s) ago
Samer Al Hadidi, Obada Ababneh, Carolina Schinke, Sharmilan Thanendrarajan, Clyde Bailey, Robert T. Smith, Susan Panozzo, Daisy Alapat, MD, Guido J. Tricot
Source: ashpublications.orgCategories: General Medicine News, Hem/OncsTweet-
We report @UAMSMyeloma the longest follow up of any myeloma phase III clinical trial @BloodAdvances @ASH_hematology #mmsm Long Term Follow up of Total Therapy IV: A Phase III Clinical Trial for Standard Risk Multiple Myeloma ➡️ https://t.co/14jmt9SjjR Median OS: 13.3 yrs 🧵 https://t.co/Ml7lgdNbj3
-
-
Mashup Score: 7
Program: Oral and Poster Abstracts Type: Oral Session: 654. Multiple Myeloma: Pharmacologic Therapies: Targeting BCMA Hematology Disease Topics & Pathways: Research, Clinical trials, Bispecific Antibody Therapy, Clinical Research, Plasma Cell Disorders, Diseases, Treatment Considerations, Biological therapies, Lymphoid Malignancies, Adverse Events Elena Zamagni, MD 1 *, Tobias Silzle, MD 2 *, Ivan Špička 3 *, Sabrin Tahri, MD 4 *, Sarah Lonergan 4 *, Inger S. Nijhof, MD, PhD 5 *, Antonietta Pia Falcone,
Source: ash.confex.comCategories: General Medicine News, Hem/OncsTweet-
#ASH24 #mmsm 1️⃣0️⃣ Majestec-4/EMN30 Trial ➡️ https://t.co/gAOFjnxR4S ✅Multiple cohorts comparing Tec alone, Tec-Len vs Len alone post ASCT- time limited maintenance in all pts Will be interesting to see if intensifying maintenance for 2 yrs will improve efficacy/safety https://t.co/KclSGJQAU1
-
-
Mashup Score: 10
Program: Oral and Poster Abstracts Type: Oral Session: 654. Multiple Myeloma: Pharmacologic Therapies: Refining the Evidence: Randomized Trials in Multiple Myeloma Hematology Disease Topics & Pathways: Research, Clinical trials, Adult, Clinical Research, Plasma Cell Disorders, Diseases, Treatment Considerations, Biological therapies, Lymphoid Malignancies, Adverse Events, Monoclonal Antibody Therapy, Study Population, Human Meletios-Athanasios Dimopoulos 1, Peter M. Voorhees, MD 2, Fredrik Schjesvold, MD,
Source: ash.confex.comCategories: General Medicine News, Hem/OncsTweet-
#ASH24 #mmsm 3️⃣ AQUILA study ➡️ https://t.co/cBxHkGczl9 ✅ Dara vs active monitoring in smoldering myeloma ✅ n=390, median F/U: 5.5 yrs ✅ORR in 2/3 of pts 🛑one third of Dara pts received second line ttt Data on progression events will be imp https://t.co/jlYZOAaqNv
-
-
Mashup Score: 12
Program: Oral and Poster Abstracts Type: Oral Session: 654. Multiple Myeloma: Pharmacologic Therapies: Refining the Evidence: Randomized Trials in Multiple Myeloma Hematology Disease Topics & Pathways: Research, Clinical trials, Clinical Research Vania Hungria, MD, PhD 1, Pawel Robak, MD, PhD 2 *, Marek Hus, MD, PhD 3 *, Vera Zherebtsova, MD 4 *, Christopher Ward, MD, PhD 5 *, Phoebe Joy Ho, MBBS 6, Roman Hajek, MD, PhD 7, Kihyun Kim, MD 8 *, Sebastian Grosicki, MD, PhD 9 *, Hanlon Sia, MBBS FRACP FRCPA
Source: ash.confex.comCategories: General Medicine News, Hem/OncsTweet-
#ASH24 #mmsm 4️⃣ DREAMM-7 OS ➡️ https://t.co/UeHKF6RUbK ✅ median OS was NR in either arm at first interim analysis, a trend in favor of BVd vs DVd, with an HR of 0.57 noted - Will see OS second interim analysis Make case of possible benefit of early BCMA based ttt(BsAb maybe) https://t.co/rovJLAHVYV
-
-
Mashup Score: 116Volume 2024 Issue 1 | Hematology, ASH Education Program | American Society of Hematology - 3 month(s) ago
Hematology, ASH Education Program | 2024 | 1 | November 2024
Source: ashpublications.orgCategories: General Medicine News, Hem/OncsTweet-
One of the best resources for trainees and attendees #ASH24 @ASH_hematology #mmsm @HemOncFellows Hematology Education Program 2024 Access: https://t.co/HtSMiawC3S Many review articles with updates across all hematological disorders https://t.co/n58itRWVdn
-
-
Mashup Score: 17
Program: Oral and Poster Abstracts Type: Oral Session: 655. Multiple Myeloma: Cellular Therapies: Unleashing Cell Therapies Against Myeloma Hematology Disease Topics & Pathways: Research, Clinical trials, Adult, Clinical Research, Plasma Cell Disorders, Chimeric Antigen Receptor (CAR)-T Cell Therapies, Diseases, Treatment Considerations, Biological therapies, Lymphoid Malignancies, Study Population, Human Ciara Louise Freeman, PhD, MSc, FRCPC, MRCP 1, Binod Dhakal, MBBS 2, Gurbakhash Kaur, MD, MA 3,
Source: ash.confex.comCategories: General Medicine News, Hem/OncsTweet-
#ASH24 #mmsm 7️⃣ IMMagine-1 Trial-Anitocabtagene autoleucel (CART-ddBCMA) ➡️ https://t.co/t8Nb52lHpi ✅n=58 pts, median FU:10.3 mo ✅ORR:95%, PFS/OS: NR 🛑5% death related to AEs Early follow up- need to follow up for AEs for longer period of time https://t.co/IrAOMgzwpy
-
-
Mashup Score: 5Paper: Prior Exposure to Belantamab Mafodotin Influences Outcomes with Idecabtagene Vicluecel in Patients with Multiple Myeloma - 3 month(s) ago
Program: Oral and Poster Abstracts Session: 907. Ou tcomes Research: Plasma Cell Disorders: Poster II Hematology Disease Topics & Pathways: Therapy sequence, Treatment Considerations Bhavesh Mohan Lal, MD 1, Marah Alzubi 2 *, Jawad Alrawabdeh 2 *, John D Shaughnessy, Jr, PhD 3 *, Fenghuang Zhan, MD 4, Eric Siegel 5 *, Carolina Schinke, MD 4, Sharmilan Thanendrarajan, MD 4, Maurizio Zangari, MD 4, Frits van Rhee, MD, PhD 6 and Samer Al Hadidi, MD, MSc 6 1 University of Arkansas for Medical Sciences, Little
Source: ash.confex.comCategories: General Medicine News, Hem/OncsTweet-
#ASH24 #mmsm @ASH_hematology Come check out poster 3789 @Dr_Bhavesh_M @UAMSMyeloma @UAMSintmedicine #ASHKudos Prior Exposure to Belantamab Mafodotin Influences Outcomes with Idecabtagene Vicluecel in Patients with Multiple Myeloma ➡️ https://t.co/xREFzVjY1F ✅ prior… https://t.co/hfGYxVFpVr https://t.co/dlERvHVqQJ
-
#mmsm @BloodJournal MIDAS study of IsaKRD-results of induction /6 cycles n=791 8% high risk cytogenetics 91% VGPR or better MRD negativity: ~ 2/3 achieved to 10-5 and 1/2 achieved 10-6 ➡️ https://t.co/mrPmR6Ked7 Imp study with post-induction MRD assessment for guiding… https://t.co/TzkuzAdRsG https://t.co/W85YwIcNf9